Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more
Neuropace Inc (NPCE) - Total Assets
Latest total assets as of September 2025: $107.25 Million USD
Based on the latest financial reports, Neuropace Inc (NPCE) holds total assets worth $107.25 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neuropace Inc - Total Assets Trend (2019–2024)
This chart illustrates how Neuropace Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neuropace Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Neuropace Inc's total assets of $107.25 Million consist of 85.9% current assets and 14.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.2% |
| Accounts Receivable | $12.85 Million | 13.6% |
| Inventory | $13.38 Million | 14.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Neuropace Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuropace Inc's current assets represent 85.9% of total assets in 2024, a decrease from 96.0% in 2019.
- Cash Position: Cash and equivalents constituted 14.2% of total assets in 2024, down from 19.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 14.1% of total assets.
Neuropace Inc Competitors by Total Assets
Key competitors of Neuropace Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Neuropace Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Neuropace Inc generates 0.84x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neuropace Inc is currently not profitable relative to its asset base.
Neuropace Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.86 | 5.59 | 5.69 |
| Quick Ratio | 3.94 | 4.77 | 4.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $75.72 Million | $ 67.81 Million | $ 44.97 Million |
Neuropace Inc - Advanced Valuation Insights
This section examines the relationship between Neuropace Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.41 |
| Latest Market Cap to Assets Ratio | 3.16 |
| Asset Growth Rate (YoY) | -12.1% |
| Total Assets | $94.65 Million |
| Market Capitalization | $299.51 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neuropace Inc's assets at a significant premium ( 3.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Neuropace Inc's assets decreased by 12.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neuropace Inc (2019–2024)
The table below shows the annual total assets of Neuropace Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $94.65 Million | -12.08% |
| 2023-12-31 | $107.65 Million | -5.66% |
| 2022-12-31 | $114.11 Million | -14.57% |
| 2021-12-31 | $133.56 Million | +138.72% |
| 2020-12-31 | $55.95 Million | +165.23% |
| 2019-12-31 | $21.09 Million | -- |